Treatment planning for heavy-ion radiotherapy: calculation and optimization of biologically effective dose

Speed and accuracy of a beam tracking system for treatment of moving targets with scanned ion beams

The technical performance of an integrated three-dimensional carbon ion pencil beam tracking system that was developed at GSI was investigated in phantom studies. Aim of the beam tracking system is to accurately treat tumours that are subject to respiratory motion with scanned ion beams. The current system provides real-time control of ion pencil beams to track a moving target laterally using the scanning magnets and longitudinally with a dedicated range shifter. The system response time was deduced to be approximately 1 ms for lateral beam tracking. The range shifter response time has been measured for various range shift amounts. A value of 16 +/- 2 ms was achieved for a water equivalent shift of 5 mm. An additional communication delay of 11 +/- 2 ms was taken into account in the beam tracking process via motion prediction. Accuracy of the lateral beam tracking was measured with a multi-wire position detector to < or =0.16 mm standard deviation. Longitudinal beam tracking accuracy was parameterized based on measured responses of the range shifter and required time durations to maintain a specific particle range. For example, 5 mm water equivalence (WE) longitudinal beam tracking results in accuracy of 1.08 and 0.48 mm WE in root mean square for time windows of 10 and 50 ms, respectively.

Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines

PURPOSE

To investigate the cytotoxic effect of high linear-energy transfer (LET) carbon irradiation on glioblastoma cells lines in combination with temozolomide (TMZ).

METHODS AND MATERIALS

The cell lines U87-MG expressing wild-type p53 and LN229 expressing both mutant and wild-type p53 were irradiated with monoenergetic carbon ion beams (LET 172 keV/microm) or an extended Bragg peak (LET 103 keV/microm) after treatment with 10 microM or 20 microM TMZ. Cytotoxicity was measured by a clonogenic survival assay, and cell growth as well as cell cycle progression, were examined.

RESULTS

The p53 mutant was more sensitive to X-ray irradiation than the p53 wild type cell line, which was also expressed in a shorter G2 block. High LET carbon ions show an increased biological effectiveness in both cell lines, which is consistent with the predictive calculations by the Local Effect Model (LEM) introduced by Scholz et al. The cell line LN229 was more sensitive to TMZ treatment than the U87MG cell line expressing wild-type p53 only. The combination of TMZ and irradiation showed an additive effect in both cell lines.

CONCLUSION

High LET carbon ion irradiation is significantly more effective for glioblastoma cell lines compared to photon irradiation. An additional treatment with TMZ may offer a great chance especially for several tumor types.

Motion compensation with a scanned ion beam: a technical feasibility study

Background

Intrafractional motion results in local over- and under-dosage in particle therapy with a scanned beam. Scanned beam delivery offers the possibility to compensate target motion by tracking with the treatment beam.

Methods

Lateral motion components were compensated directly with the beam scanning system by adapting nominal beam positions according to the target motion. Longitudinal motion compensation to mitigate motion induced range changes was performed with a dedicated wedge system that adjusts effective particle energies at isocenter.

Results

Lateral compensation performance was better than 1% for a homogeneous dose distribution when comparing irradiations of a stationary radiographic film and a moving film using motion compensation. The accuracy of longitudinal range compensation was well below 1 mm.

Conclusion

Motion compensation with scanned particle beams is technically feasible with high precision.

A treatment planning code for inverse planning and 3D optimization in hadrontherapy

The therapeutic use of protons and ions, especially carbon ions, is a new technique and a challenge to conform the dose to the target due to the energy deposition characteristics of hadron beams. An appropriate treatment planning system (TPS) is strictly necessary to take full advantage. We developed a TPS software, ANCOD++, for the evaluation of the optimal conformal dose. ANCOD++ is an analytical code using the voxel-scan technique as an active method to deliver the dose to the patient, and provides treatment plans with both proton and carbon ion beams. The iterative algorithm, coded in C++ and running on Unix/Linux platform, allows the determination of the best fluences of the individual beams to obtain an optimal physical dose distribution, delivering a maximum dose to the target volume and a minimum dose to critical structures. The TPS is supported by Monte Carlo simulations with the package GEANT3 to provide the necessary physical lookup tables and verify the optimized treatment plans. Dose verifications done by means of full Monte Carlo simulations show an overall good agreement with the treatment planning calculations. We stress the fact that the purpose of this work is the verification of the physical dose and a next work will be dedicated to the radiobiological evaluation of the equivalent biological dose.

Accuracy of the local effect model for the prediction of biologic effects of carbon ion beams in vitro and in vivo

PURPOSE

To analyze the accuracy of relative biologic effectiveness (RBE) values for treatment planning in carbon ion radiotherapy based on the local effect model (LEM) and to discuss the implications on the clinically relevant depth dose profiles.

METHODS AND MATERIALS

Predictions of the LEM are compared with a broad panel of experimental data in vitro and to the tolerance of the rat spinal cord in vivo. To improve the accuracy of the LEM, the description of track structure is modified by taking into account a velocity-dependent extension of the inner part of the track.

RESULTS

The original version of the LEM (LEM I) underestimates the therapeutic ratio of carbon ions (i.e., the ratio of RBE in the Bragg peak region as compared with the RBE in the entrance channel). Although significantly reduced, the cluster extension of the LEM (LEM II) still shows the same tendency. Implementation of the modified track structure (LEM III) almost completely compensates these systematic deviations, and predictions of RBE by LEM III for high and low energetic carbon ions show good agreement for a wide panel of different cell lines, as well as for the tolerance of the rat spinal cord. As a consequence, the expected RBE in the normal tissue surrounding the tumor becomes significantly lower than estimated with the LEM in its original version (LEM I).

CONCLUSIONS

The modified track structure description represents an empiric approach to improve the accuracy of the LEM for treatment planning. This will be particularly useful for further optimization of carbon ion therapy in general and with respect to comparison with other treatment modalities, such as protons or intensity-modulated radiotherapy.

Radiobiologic parameters and local effect model predictions for head-and-neck squamous cell carcinomas exposed to high linear energy transfer ions

PURPOSE

To establish the radiobiologic parameters of head-and-neck squamous cell carcinomas (HNSCC) in response to ion irradiation with various linear energy transfer (LET) values and to evaluate the relevance of the local effect model (LEM) in HNSCC.

METHODS AND MATERIALS

Cell survival curves were established in radiosensitive SCC61 and radioresistant SQ20B cell lines irradiated with [33.6 and 184 keV/n] carbon, [302 keV/n] argon, and X-rays. The results of ion experiments were confronted to LEM predictions.

RESULTS

The relative biologic efficiency ranged from 1.5 to 4.2 for SCC61 and 2.1 to 2.8 for SQ20B cells. Fixing an arbitrary D(0) parameter, which characterized survival to X-ray at high doses (>10 Gy), gave unsatisfying LEM predictions for both cell lines. For D(0) = 10 Gy, the error on survival fraction at 2 Gy amounted to a factor of 10 for [184 keV/n] carbon in SCC61 cells. We showed that the slope (s(max)) of the survival curve at high doses was much more reliable than D(0). Fitting s(max) to 2.5 Gy(-1) gave better predictions for both cell lines. Nevertheless, LEM could not predict the responses to fast and slow ions with the same accuracy.

CONCLUSIONS

The LEM could predict the main trends of these experimental data with correct orders of magnitude while s(max) was optimized. Thus the efficiency of carbon ions cannot be simply extracted from the clinical response of a patient to X-rays. LEM should help to optimize planning for hadrontherapy if a set of experimental data is available for high-LET radiations in various types of tumors.

Direct comparison of biologically optimized spread-out bragg peaks for protons and carbon ions

PURPOSE

In radiotherapy with hadrons, it is anticipated that carbon ions are superior to protons, mainly because of their biological properties: the relative biological effectiveness (RBE) for carbon ions is supposedly higher in the target than in the surrounding normal tissue, leading to a therapeutic advantage over protons. The purpose of this report is to investigate this effect by using biological model calculations.

METHODS AND MATERIALS

We compared spread-out Bragg peaks for protons and carbon ions by using physical and biological optimization. The RBE for protons and carbon ions was calculated according to published biological models. These models predict increased RBE values in regions of high linear energy transfer (LET) and an inverse dependency of the RBE on dose.

RESULTS

For pure physical optimization, protons yield a better dose distribution along the central axis. In biologically optimized plans, RBE variations for protons were relatively small. For carbon ions, high RBE values were found in the high-LET target region, as well as in the low-dose region outside the target. This means that the LET dependency and dose dependency of the RBE can cancel each other. We show this for radioresistant tissues treated with two opposing beams, for which the predicted carbon RBE within the target volume was lower than outside.

CONCLUSIONS

For tissue parameters used in this study, the model used does not predict a biologic advantage of carbon ions. More reliable model parameters and clinical trials are necessary to explore the true potential of radiotherapy with carbon ions.

4D treatment planning for scanned ion beams

At Gesellschaft für Schwerionenforschung (GSI) more than 330 patients have been treated with scanned carbon ion beams in a pilot project. To date, only stationary tumors have been treated. In the presence of motion, scanned ion beam therapy is not yet possible because of interplay effects between scanned beam and target motion which can cause severe mis-dosage. We have started a project to treat tumors that are subject to respiratory motion. A prototype beam application system for target tracking with the scanned pencil beam has been developed and commissioned.

To facilitate treatment planning for tumors that are subject to organ motion, we have extended our standard treatment planning system TRiP to full 4D functionality. The 4D version of TRiP allows to calculate dose distributions in the presence of motion. Furthermore, for motion mitigation techniques tracking, gating, rescanning, and internal margins optimization of treatment parameters has been implemented. 4D calculations are based on 4D computed tomography data, deformable registration maps, organ motion traces, and beam scanning parameters.

We describe the methods of our 4D treatment planning approach and demonstrate functionality of the system for phantom as well as patient data.

Effectiveness of Carbon Ion Radiotherapy in the Treatment of Skull-Base Chordomas

PURPOSE

The aim of this study was to evaluate the effectiveness and toxicity of carbon ion radiotherapy in chordomas of the skull base.

METHODS AND MATERIALS

Between November 1998 and July 2005, a total of 96 patients with chordomas of the skull base have been treated with carbon ion radiation therapy (RT) using the raster scan technique at the Gesellschaft für Schwerionenforschung (GSI) in Darmstadt, Germany. All patients had gross residual tumors. Median total dose was 60 CGE (range, 60-70 CGE) delivered in 20 fractions within 3 weeks. Local control and overall survival rates were calculated using the Kaplan-Meier method. Toxicity was assessed according to the Common Terminology Criteria (CTCAE v.3.0) and the Radiation Therapy Oncology Group (RTOG) / European Organization for Research and Treatment of Cancer (EORTC) score.

RESULTS

Mean follow-up was 31 months (range, 3-91 months). Fifteen patients developed local recurrences after carbon ion RT. The actuarial local control rates were 80.6% and 70.0% at 3 and 5 years, respectively. Target doses in excess of 60 CGE and primary tumor status were associated with higher local control rates. Overall survival was 91.8% and 88.5% at 3 and 5 years, respectively. Late toxicity consisted of optic nerve neuropathy RTOG/EORTC Grade 3 in 4.1% of the patients and necrosis of a fat plomb in 1 patient. Minor temporal lobe injury (RTOG/EORTC Grade 1-2) occurred in 7 patients (7.2%).

CONCLUSIONS

Carbon ion RT offers an effective treatment option for skull-base chordomas with acceptable toxicity. Doses in excess of 75 CGE with 2 CGE per fraction are likely to increase local control probability.

European developments in radiotherapy with beams of large radiobiological effectiveness

This paper reviews the European activities in the field of tumour therapy with beams which have a Radio Biological Effectiveness (RBE) larger than 1. Initially neutron beams have been used. Then charged pions promised better cure rates so that their use was pursued in the framework of the ;Piotron' project at the Paul Scherrer Institute (Switzerland). However both approaches did not meet the expectations and in the 80s the EULIMA project became the flagship of these attempts to improve the effects of the delivery of radiation doses of large RBE with respect to photons, electrons and even protons. The EULIMA ion accelerator was never built and it took more than ten years to see the approval, in Heidelberg and Pavia, of the construction of the HIT and CNAO ;dual' centres for carbon ions and protons. In 2008 they will start treating patients. The developments that brought to these construction projects are described together with the special features of these two facilities. The third European dual centre is being built by Siemens Medical Systems in Marburg, Germany, while other facilities have been approved but not yet fully financed in Wiener Neustadt (Austria), Lyon (France) and Uppsala (Sweden). Finally the collaboration activities of the European Network ENLIGHT are presented together with the recent involvements of European industries in the construction of turn-key dual centres and the development of a new accelerator concept for hadrontherapy, the ;cyclinac'.

Specifying carbon ion doses for radiotherapy: the heidelberg approach

There are currently no guidelines for prescribing and reporting radiation therapy (RT) with ion beams. In this paper an overview over some technical aspects and their implication on ion RT are reported. This includes a discussion of the difference in the treatment planning systems currently used for active and passive beam shaping systems, aspects of patient positioning and target definition and dose prescription. Special emphasis is put on the questions arising from the use of the beam scanning methods in combination with biological treatment plan optimization, which is used in the German heavy ion therapy facility at GSI and will also be introduced at the hospital based facility in Heidelberg. Furthermore, the Heidelberg approach for the clinical dose prescription is compared with the methods developed at HIMAC in Chiba, Japan.

Radiation tolerance of the rat spinal cord after 6 and 18 fractions of photons and carbon ions: Experimental results and clinical implications

PURPOSE

The tolerance of the rat spinal cord to photon and carbon ion irradiations was investigated to determine the relative biologic effectiveness (RBE) of carbon ions ((12)C) in the plateau region and in a 1 cm spread-out Bragg-peak.

METHODS AND MATERIALS

The cranial part of the cervical and thoracic spinal cord of 336 rats was irradiated with 6 or 18 fractions (Fx) of photons or (12)C-ions, respectively. Animals were followed up for 300 days for the onset of paresis grade II and dose-response curves were calculated.

RESULTS

The D(50)-values (dose at 50% complication probability) were 42.9 +/- 0.5 Gy, 62.2 +/- 0.9 Gy (6 and 18 Fx, (12)C-plateau) and 19.2 +/- 0.2 Gy, 17.6 +/- 0.2 Gy (6 and 18 Fx (12)C-peak), respectively. For photons, the D(50)-values were 57.0 +/- 0.7 Gy for 6 and 88.6 +/- 0.7 Gy for 18 Fx. The corresponding RBE-values were 1.33 +/- 0.02, 1.42 +/- 0.02 (6 and 18 Fx, (12)C-plateau) and 2.97 +/- 0.05, 5.04 +/- 0.08 (6 and 18 Fx (12)C-peak), respectively. Including data of a previously performed experiment for 1 and 2 Fx (1) the parameter alpha/beta of the LQ-model was found to be 2.8 +/- 0.4 Gy, 2.1 +/- 0.4 Gy and 37.0 +/- 5.3 Gy for photon-, (12)C-plateau- and (12)C-peak irradiations, respectively.

CONCLUSIONS

Carbon ion irradiations of the spinal cord are significantly more effective in the peak than in the plateau region. The alpha/beta-values indicate a significant fractionation effect only for the plateau irradiations. In the Bragg-peak, the applied RBE-model correctly describes the main features although it generally underestimates the RBE by 25%. In the plateau region, maximum deviations of up to 20% were found. The acquired data contribute significantly to the validation of the applied RBE-model.

Carbon ion radiotherapy of skull base chondrosarcomas

PURPOSE

To evaluate the effectiveness and toxicity of carbon ion radiotherapy in chondrosarcomas of the skull base.

PATIENTS AND METHODS

Between November 1998 and September 2005, 54 patients with low-grade and intermediate-grade chondrosarcomas of the skull base have been treated with carbon ion radiation therapy (RT) using the raster scan technique at the Gesellschaft für Schwerionenforschung in Darmstadt, Germany. All patients had gross residual tumors after surgery. Median total dose was 60 CGE (weekly fractionation 7 x 3.0 CGE). All patients were followed prospectively in regular intervals after treatment. Local control and overall survival rates were calculated using the Kaplan-Meier method. Toxicity was assessed according to the Common Terminology Criteria (CTCAE v.3.0) and the Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer (EORTC) score.

RESULTS

Median follow-up was 33 months (range, 3-84 months). Only 2 patients developed local recurrences. The actuarial local control rates were 96.2% and 89.8% at 3 and 4 years; overall survival was 98.2%at 5 years. Only 1 patient developed a mucositis CTCAE Grade 3; the remaining patients did not develop any acute toxicities >CTCAE Grade 2. Five patients developed minor late toxicities (RTOG/EORTC Grades 1-2), including bilateral cataract (n = 1), sensory hearing loss (n = 1), a reduction of growth hormone (n = 1), and asymptomatic radiation-induced white matter changes of the adjacent temporal lobe (n = 2). Grade 3 late toxicity occurred in 1 patient (1.9%) only.

CONCLUSIONS

Carbon ion RT is an effective treatment for low- and intermediate-grade chondrosarcomas of the skull base offering high local control rates with low toxicity.

Radiation Therapy With Charged Particles

Charged particle beams can offer an improved dose conformation to the target volume as compared with photon radiotherapy, with better sparing of normal tissue structures close to the target. In addition, beams of ions heavier than (4)He exhibit a strong increase of the linear energy transfer in the Bragg peak as compared with the entrance region. These physical and biological properties are much more favorable than in photon radiotherapy. As a consequence, particle therapy with protons and heavy ions has gained increasing interest worldwide, and many clinical centers are considering introducing radiation therapy with charged particles. This contribution summarizes the physical and technical principles of charged particle therapy with protons and heavy ions. It briefly reviews the clinical experience gathered so far with proton therapy and gives a more detailed summary of the recent results in carbon ion therapy of skull base tumors, head and neck tumors, non-small-cell lung cancer, hepatocellular carcinomas, bone and soft-tissue sarcomas, and prostate cancer.

Simulations to design an online motion compensation system for scanned particle beams

Respiration-induced target motion is a major problem in intensity-modulated radiation therapy. Beam segments are delivered serially to form the total dose distribution. In the presence of motion, the spatial relation between dose deposition from different segments will be lost. Usually, this results in over- and underdosage. Besides such interplay effects between target motion and dynamic beam delivery as known from photon therapy, changes in internal density have an impact on delivered dose for intensity-modulated charged particle therapy. In this study, we have analysed interplay effects between raster scanned carbon ion beams and target motion. Furthermore, the potential of an online motion strategy was assessed in several simulations. An extended version of the clinical treatment planning software was used to calculate dose distributions to moving targets with and without motion compensation. For motion compensation, each individual ion pencil beam tracked the planned target position in the lateral as well as longitudinal direction. Target translations and rotations, including changes in internal density, were simulated. Target motion simulating breathing resulted in severe degradation of delivered dose distributions. For example, for motion amplitudes of +/-15 mm, only 47% of the target volume received 80% of the planned dose. Unpredictability of resulting dose distributions was demonstrated by varying motion parameters. On the other hand, motion compensation allowed for dose distributions for moving targets comparable to those for static targets. Even limited compensation precision (standard deviation approximately 2 mm), introduced to simulate possible limitations of real-time target tracking, resulted in less than 3% loss in dose homogeneity.

Fast multifield optimization of the biological effect in ion therapy

In this paper, we present a new technique for simultaneous multifield optimization of the biological effect (i.e. relative biological effectiveness times dose) for intensity modulated radiotherapy with ion beams. It offers complete inverse treatment planning by taking into account planning constraints for the target volume as well as for organs at risk. The approach is based on the mixed irradiation formalism of the linear-quadratic model from radiobiology. We employ a novel objective function to directly optimize the biological effect rather than the physical dose. The required biological input data are reduced to a minimum and are completely independent from the optimization itself. They can be derived from any radiobiological model or even from directly measured data. The new optimization method was fully integrated into our inverse treatment planning tool KonRad. Comparisons with the TRiP98 treatment planning code were done for simple spread-out Bragg peaks as well as for three-dimensional treatment plans, where all fields were optimized separately. While the agreement between both planning systems was very good, the calculation time was substantially reduced in KonRad. By enabling the multifield optimization, the quality of the treatment plans and the sparing of healthy tissues can be clearly improved.

Rapid calculation of biological effects in ion radiotherapy

We describe a method for fast calculation of biological effects after ion irradiation. It is an alternative derivative of the established local effect model (LEM) and has been integrated into GSI's TRiP98 treatment planning system. We show that deviations from our classic approach for treatment planning are less than 5% for therapeutical doses, but calculational speed can be improved by one to two orders of magnitude. This will allow sophisticated methods of treatment planning for ion irradiation, taking biological effects fully into account.

Detailed analysis of the cell-inactivation mechanism by accelerated protons and light ions

A detailed study of the biological effects of diverse quality radiations, addressing their biophysical interpretation, is presented. Published survival data for V79 cells irradiated by monoenergetic protons, helium-3, carbon and oxygen ions and for CHO cells irradiated by carbon ions have been analysed using the probabilistic two-stage model of cell inactivation. Three different classes of DNA damage formed by traversing particles have been distinguished, namely severe single-track lesions which might lead to cell inactivation directly, less severe lesions where cell inactivation is caused by their combinations and lesions of negligible severity that can be repaired easily. Probabilities of single ions forming these lesions have been assessed in dependence on their linear energy transfer (LET) values. Damage induction probabilities increase with atomic number and LET. While combined lesions play a crucial role at lower LET values, single-track damage dominates in high-LET regions. The yields of single-track lethal lesions for protons have been compared with Monte Carlo estimates of complex DNA lesions, indicating that lethal events correlate well with complex DNA double-strand breaks. The decrease in the single-track damage probability for protons of LET above approximately 30 keV microm(-1), suggested by limited experimental evidence, is discussed, together with the consequent differences in the mechanisms of biological effects between protons and heavier ions. Applications of the results in hadrontherapy treatment planning are outlined.

Examination of GyE system for HIMAC carbon therapy

PURPOSE

A retrospective analysis was made to examine appropriateness in the estimation of the biologic effectiveness of carbon-ion radiotherapy using resultant data from clinical trials at the heavy-ion medical accelerator complex (HIMAC) at the National Institute of Radiological Sciences in Chiba, Japan.

METHODS AND MATERIALS

At HIMAC, relative biologic effectiveness (RBE) values of therapeutic carbon beams were determined based on experimental results of cell responses, on values expected with the linear-quadratic model, and based on experiences with neutron therapy. We use fixed RBE values independent of dose levels, although this apparently contradicts radiobiologic observations. Our RBE system depends only on LET of the heavy-ion radiation fields. With this RBE system, over 2,000 patients have been treated by carbon beams. With data from these patients, the local control rate of non-small-cell lung cancer was analyzed to verify the clinical RBE of the carbon beam. The local control rate was compared with rates published by groups from Gunma University and Massachusetts General Hospital. Using a simplified tumor control probability (TCP) model, clinical RBE values were obtained for different levels of TCP.

RESULTS

For the 50% level of the clinical TCP, the RBE values nearly coincide with those for in vitro human salivary gland cell survival at 10%. For the higher levels of clinical TCP, the RBE values approach closer to those adapted in clinical trials at HIMAC.

Towards biology-oriented treatment planning in hadrontherapy

By representing damage induction by ionising particles and its repair by the cell, the probabilistic two-stage model provides a detailed description of the main processes involved in cell killing by radiation. To link this model with issues of interest in hadron radiotherapy, a simple Bragg peak model is used. Energy-loss, its straggling and the attenuation of the primary particle fluence are represented in a simplified way, based on semi-phenomenological formulas and energy-loss tables. An effective version of the radiobiological model, considering residual (unrepaired) lesions only, is joined with the simple physical model to estimate cell survival along ions' penetration depth. The predicted survival ratios for CHO cells irradiated by carbon ions are presented, showing very good agreement with experimental data.

Test of the local effect model using clinical data: tumour control probability for lung tumours after treatment with carbon ion beams

The treatment planning approach used within the heavy ion tumour therapy project at GSI Darmstadt includes a biological optimisation, which is based on a biophysical model, the Local Effect Model (LEM). Here we show that the predictions of the LEM are in good agreement with clinical data obtained at the HIMAC in Chiba for the treatment of non-small-cell lung cancer, and the steep dose response for carbon ions is reproduced correctly. This steeper increase corresponds to an increasing RBE with increasing dose, which apparently is in contradiction to the systematics observed in general for in vitro measurements. A possible explanation of this discrepancy is based on the interindividual variation of photon sensitivity.

RBE of carbon ions: experimental data and the strategy of RBE calculation for treatment planning

The main reason for the application of heavy ions like carbon in radiotherapy is the enhanced relative biological effectiveness RBE. In contrast to neutrons where RBE is widely independent from penetration depth, high energy carbon beams have a low RBE at the entrance and a high RBE in the target-volume. Therefore, the side effects to normal tissue are small, while the tumor response can be maximized. In the paper, experimental RBE values for inactivation are compiled, that demonstrate the RBE dependence from the repair capacity. In a theoretical approach, the local effect model (LEM), this dependence is used to calculate clinical RBE. Examples for clinical RBEs are given that have been applied to patient treatments.

Optimization of radiobiological effects in intensity modulated proton therapy

Today, inverse treatment planning for intensity modulated proton therapy (IMPT) usually employs a constant relative biological effectiveness (RBE). In this paper, the potential clinical relevance of RBE variations for scanning techniques in IMPT is investigated, and a new strategy to include the RBE into the inverse planning process is presented. Three-dimensional RBE distributions are calculated based on a phenomenological model that describes the RBE as a function of dose, linear energy transfer (LET) and tissue type in the framework of the linear-quadratic model. This RBE model is integrated into the optimization loop of inverse planning by using a modified version of the standard quadratic objective function, where the physical dose is replaced by the biological effect. This system for "biological optimization" was implemented into a research version of the inverse planning software KonRad and allows the direct optimization of the product of RBE and physical dose. Several treatment plans for a prostate case are presented, which compare the biological with the conventional physical dose optimization for IMPT scanning techniques, in particular distal edge tracking (DET) and the full three-dimensional (3D) modulation of beam spots. Mainly due to their different LET distributions, the RBE effects for these two techniques are quite different: while the RBE distribution was more or less homogeneous in the planning target volume (PTV) for 3D modulation, considerable RBE variations within the PTV were observed for DET. These unfavorable effects could be compensated for by employing the new biological objective function, which led to a more homogeneous distribution of the product of RBE and physical dose in the PTV. The computation time increased by a factor of 2 compared to the optimization of the physical dose. In conclusion, the proposed method allows the simultaneous multifield optimization of the biological effect in a reasonable time, and is therefore well suited for studying the influence of a variable RBE in IMPT as well as for minimizing potentially adverse effects.

Online compensation for target motion with scanned particle beams: simulation environment

Target motion is one of the major limitations of each high precision radiation therapy. Using advanced active beam delivery techniques, such as the magnetic raster scanning system for particle irradiation, the interplay between time-dependent beam and target position heavily distorts the applied dose distribution. This paper presents a simulation environment in which the time-dependent effect of target motion on heavy-ion irradiation can be calculated with dynamically scanned ion beams. In an extension of the existing treatment planning software for ion irradiation of static targets (TRiP) at GSI, the expected dose distribution is calculated as the sum of several sub-distributions for single target motion states. To investigate active compensation for target motion by adapting the position of the therapeutic beam during irradiation, the planned beam positions can be altered during the calculation. Applying realistic parameters to the planned motion-compensation methods at GSI, the effect of target motion on the expected dose uniformity can be simulated for different target configurations and motion conditions. For the dynamic dose calculation, experimentally measured profiles of the beam extraction in time were used. Initial simulations show the feasibility and consistency of an active motion compensation with the magnetic scanning system and reveal some strategies to improve the dose homogeneity inside the moving target. The simulation environment presented here provides an effective means for evaluating the dose distribution for a moving target volume with and without motion compensation. It contributes a substantial basis for the experimental research on the irradiation of moving target volumes with scanned ion beams at GSI which will be presented in upcoming papers.

Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques

BACKGROUND

The authors evaluated whether modern photon techniques, such as stereotactic fractionated radiation therapy (FSRT) or intensity-modulated RT, outweighed the biologic advantages of high-linear-energy transfer RT in the treatment of patients with locally advanced adenoid cystic carcinomas (ACC) that infiltrated the skull base or the orbit.

METHODS

Between June 1995 and December 2003, 63 patients with ACC were treated with modern RT techniques at the University of Heidelberg. The treatment results achieved with modern photon techniques alone were compared with the results achieved with combined photon RT and a carbon ion boost. Twenty-nine patients (Group A) were treated with a combination of photon RT and a carbon ion boost. Thirty-four patients (Group B) received photon RT alone.

RESULTS

The median follow-up was 16 months for Group A and 24 months for Group B. Locoregional control rates at 2 years and 4 years were 77.5% and 77.5% for Group A and 72.2% and 24.6% for Group B, respectively (P = 0.08; log-rank test). Disease-free and overall survival rates at 2 years/4 years were 71.5%/53% and 86.6%/75.8% for Group A and 69.2%/23% and 77.9%/77.9% for Group B, respectively. Rates for severe late toxicity were < 5% for both groups.

CONCLUSIONS

Modern RT techniques allowed the safe delivery of high target doses to patients with locally advanced ACC. Late toxicity rates were kept lower compared with the historic neutron therapy data. A combination of modern photon RT and carbon ion RT seemed to be advantageous, with a trend toward higher locoregional control rates compared with modern photon RT alone.

Carbon ion radiation therapy for chordomas and low grade chondrosarcomas - current status of the clinical trials at GSI-

Carbon ion radiation therapy (RT) is available at the German Ion Research Center (GSI) in Darmstadt, Germany, since December 1997. Patient treatments within the pilot project are carried out by radiation oncologists of the University of Heidelberg in cooperation with the Department of Biophysics of GSI, the Division of Medical Physics of the German Cancer Research Center Heidelberg and the Research Center Rossendorf. Patients are treated within three beam time blocks of 20 days per year at the basic physics research center at GSI, the overall capacity per year being 45 to 50 patients. Main purpose of the pilot project was to investigate carbon ion radiation therapy for different tumor entities within clinical phase I/II trials. This manuscript updates the results of the clinical phase I/II trial of carbon ion RT in chordomas and low grade chondrosarcomas of the skull base and summarizes the current status of the ongoing phase I/II trial for extracranial chordomas and low grade chondrosarcomas.

Heavy ion radiobiology for hadrontherapy and space radiation protection

Research in the field of biological effects of heavy charged particles is needed for both heavy-ion therapy (hadrontherapy) and protection from the exposure to galactic cosmic radiation in long-term manned space missions. Although the exposure conditions (e.g. high- vs. low-dose rate) and relevant endpoints (e.g. cell killing vs. neoplastic transformation) are different in the two fields, it is clear that a substantial overlap exists in several research topics. Three such topics are discussed in this short review: individual radiosensitivity, mixed radiation fields, and late stochastic effects of heavy ions. In addition, researchers involved either in experimental studies on space radiation protection or heavy-ion therapy will basically use the same accelerator facilities. It seems to be important that novel accelerator facilities planned (or under construction) for heavy-ion therapy reserve a substantial amount of beamtime to basic studies of heavy-ion radiobiology and its applications in space radiation research.

Treatment planning for carbon ion radiotherapy in Germany: Review of clinical trials and treatment planning studies

The GSI carbon ion radiotherapy facility established the first completely active beam shaping system for heavy ions, using energy variation on the synchrotron and pencil beam scanning. The introduction of an active beam shaping system for carbon ions has considerable impact on the design of the treatment planning system (TPS). The TPS has to account for the capability of the beam delivery and the biological modelling, which is needed to calculate the RBE for the resulting varying depth dose modulation. The TPS used in clinical routine with carbon ions is described and its use in treatment planning studies are outlined. A clinical trial with carbon ion therapy as primary therapy for chordoma and chondrosarcoma of the base of skull has been completed in 2001. Currently, carbon ion therapy as a boost treatment together with conventional conformal photon therapy or IMRT is under investigation in clinical trials for adenoid cystic carcinoma, chordoma and chondrosarcoma of the cervical spine and sacrococcygeal chordoma. Treatment planning studies comparing carbon ion therapy with IMRT, using optimization of combination therapy, and optimization of beam-line design have already been completed. Analysis of uncertainties in treatment planning has been started with the investigation of range uncertainties stemming from CT imaging. Uncertainties coming from the beam delivery play only a minor role. An attempt to asses the uncertainties introduced in treatment plans by the biological modelling, was done, using phantom verification of calculated cell survival levels. The clinical trials and planning studies are of special importance for the upcoming new clinical ion facility of the Heidelberg university hospital.

Treatment planning for scanned ion beams

Since 1997 a radiotherapy unit using fast carbon ions is operational at GSI. An intensity-controlled magnetic raster scanner together with a synchrotron allowing fast energy variation enable a unique method of purely active dose shaping in three dimensions. This contribution describes the necessary steps to establish a treatment planning system for this novel modality. We discuss the requirements for the physical beam model and the radiobiological model. Based on these we chose to implement a home-grown pencil beam model to describe the ion-tissue interaction and the Local Effect Model to calculate the RBE voxel-by-voxel. Given the large number of degrees of freedom biological dose optimization must be achieved by means of inverse treatment planning. All ion-related aspects are collected in our TRiP98 software. Biological dosimetry measuring cell survival in two dimensions turns out to be a good way to verify the model predictions as well as the actual irradiation procedure. We show a patient example and outline the future steps towards a dedicated clinic facility for all light ions.

Late effects from hadron therapy

Successful cancer patient survival and local tumor control from hadron radiotherapy warrant a discussion of potential secondary late effects from the radiation. The study of late-appearing clinical effects from particle beams of protons, carbon, or heavier ions is a relatively new field with few data. However, new clinical information is available from pioneer hadron radiotherapy programs in the USA, Japan, Germany and Switzerland. This paper will review available data on late tissue effects from particle radiation exposures, and discuss its importance to the future of hadron therapy. Potential late radiation effects are associated with irradiated normal tissue volumes at risk that in many cases can be reduced with hadron therapy. However, normal tissues present within hadron treatment volumes can demonstrate enhanced responses compared to conventional modes of therapy. Late endpoints of concern include induction of secondary cancers, cataract, fibrosis, neurodegeneration, vascular damage, and immunological, endocrine and hereditary effects. Low-dose tissue effects at tumor margins need further study, and there is need for more acute molecular studies underlying late effects of hadron therapy.

The modelling of positron emitter production and PET imaging during carbon ion therapy

At the carbon ion therapy facility of GSI Darmstadt in-beam positron emission tomography (PET) is used for imaging the beta+-activity distributions which are produced via nuclear fragmentation reactions between the carbon ions and the atomic nuclei of the irradiated tissue. On the basis of these PET images the quality of the irradiation, i.e. the position of the field, the particle range in vivo and even local deviations between the planned and the applied dose distribution, can be evaluated. However, for such an evaluation the measured beta+-activity distributions have to be compared with those predicted from the treatment plan. The predictions are calculated as follows: a Monte Carlo event generator produces list mode data files of the same format as the PET scanner in order to be processed like the measured ones for tomographic reconstruction. The event generator models the whole chain from the interaction of the projectiles with the target, i.e. their stopping and nuclear reactions, the production and the decay of positron emitters, the motion of the positrons as well as the propagation and the detection of the annihilation photons. The steps of the modelling, the experimental validation and clinical implementation are presented.

The LET spectra at different penetration depths along secondary9C and11C beams

Owing to the potentially therapeutic enhancement of delayed particles in treating malignant diseases by radioactive 9C-ion beam, LET spectra at different penetration depths for a 9C beam with 5% momentum spread, produced in the secondary beam line (SBL) at HIMAC, were measured with a multi-wire parallel-plate proportional counter. To compare these LET spectra with those of a therapeutic 12C beam under similar conditions, the 12C beam was replaced with an 11C beam, yielded in the SBL as well and having almost the same range as that of the 9C beam. The LET spectra of the 9C beam and its counterpart, i.e. the 11C beam, at various depths were compared, especially around the Bragg peak regions. The results show that nearby the Bragg peak lower LET components decreased in the LET spectra of the 9C beam while extra components between the LET peak caused by the primary beam and the lower components due to the fragments could be observed. These additional contributions in the LET spectra could be attributed to parts of the emitted particles from the radioactive 9C ions with suitable conditions regarding the LET counter. Integrating these LET spectra in different manners, depth-dose and dose-averaged LET distributions were obtained for the 9C and 11C beams, forming the basic data sets for further studies. In general, the depth-dose distributions of the 9C and 11C beams are comparative, i.e. almost the same peak-to-plateau ratio. The ratio for the 9C beam, however, has room to increase due to the geometric structure limitation of the present detector. The dose-averaged LETs along the beam penetration are always lower for the 9C beam than for the 11C beam except at the falloff region beyond the Bragg peak. Applying the present depth-dose and dose-averaged LET data sets as well as the essential radiobiological parameters obtained with 12C beams previously for HSG cells, an estimate concerning the HSG cell surviving effects along the penetration of the 9C and 11C beams shows that lower survival fractions for the 9C beam at the distal part of the Bragg peak, corresponding to the stopping region of the incoming 9C ions, can be expected when the same entrance dose is given. It is still hard to appreciate the potential of 9C beams in cancer therapy based on the present LET spectrum measurement, but it provides a substantial basis for upcoming radiobiological experiments.

The increased biological effectiveness of heavy charged particles: from radiobiology to treatment planning

The increased biological effectiveness of heavy charged particle beams like e.g., carbon ions in the tumor volume in comparison to the lower effectiveness in the surrounding healthy tissue represents one of the major rationales for their application in tumor therapy. This increased effectiveness also characterizes the advantage of heavier ions compared to proton beams. The increased effectiveness has to be taken into account in treatment planning in order to estimate the corresponding photon equivalent doses in normal and tumor tissues, thus allowing a link e.g., to normal tissue dose limits in conventional photon therapy. Due to the complex dependencies of RBE on parameters like dose, beam energy, LET, atomic number and cell or tissue type, the relevant RBEs cannot be solely determined from experimental data. Therefore, within the framework of the pilot project of tumor therapy with carbon ions performed at GSI Darmstadt, treatment planning is based on a biophysical model, which has been extensively tested. The paper first summarizes the essential systematic dependencies of RBE on different parameters like e.g., dose, LET, atomic number and cell type. The basic principle of the biophysical model is then introduced, and special emphasis is given to the application of the model to in vivo and clinical endpoints. Model predictions are compared to experimental data in vitro and in vivo. Finally, the implementation of the biophysical model in the treatment planning procedure is presented. The biological verification of the whole treatment planning procedure is explained and examples of patient treatment plans are given.

A calibration procedure for beam monitors in a scanned beam of heavy charged particles

An international code of practice (CoP) for dosimetry based on standards of absorbed dose to water has recently been published by the IAEA [Technical Report Series No. 398, 2000] (TRS-398). This new CoP includes procedures for proton and heavy ion beams as well as all other beam qualities. In particular it defines reference conditions to which dose measurements should refer to. For proton and ion beams these conditions include dose measurements in the center of all possible modulated Bragg peaks. The recommended reference conditions in general are used also for the calibration of beam monitors. For a dynamic beam delivery system using beam scanning in combination with energy variation, like, e.g., at the German carbon ion radiotherapy facility, this calibration procedure is not appropriate. We have independently developed a different calibration procedure. Similar to the IAEA CoP this procedure is based on the measurement of absorbed dose to water. This is translated in terms of fluence which finally results in an energy-dependent calibration of the beam monitor in units of particle number per monitor unit, which is unique for all treatment fields. In contrast to the IAEA CoP, the reference depth is chosen to be very small. The procedure enables an accurate and reliable determination of calibration factors. In a second step, the calibration is verified by measurements of absorbed dose in various modulated Bragg peaks by comparing measured against calculated doses. The agreement between measured and calculated doses is usually better than 1% for homogeneous fields and the mean deviation for more inhomogeneous treatment fields, as they are used for patient treatments, is within 3%. It is proposed that the CoP in general, and in particular the IAEA TRS-398 should include explicit recommendations for the beam monitor calibration. These recommendations should then distinguish between systems using static and dynamic beams.

Results of carbon ion radiotherapy in 152 patients

PURPOSE

This study summarizes the experience with raster scanned carbon ion radiation therapy (RT) at the Gesellschaft für Schwerionenforschung (GSI), Darmstadt, Germany since 1997.

METHODS AND MATERIALS

Between December 1997 and December 2002, 152 patients were treated at GSI with carbon ion RT. Eighty-seven patients with chordomas and low-grade chondrosarcomas of the skull base received carbon ion RT alone (median dose 60 GyE); 21 patients with unfavorable adenoid cystic carcinomas and 17 patients with spinal (n = 9) and sacrococcygeal (n = 8) chordomas and chondrosarcomas were treated with combined photon and carbon ion RT. Twelve patients received reirradiation with carbon ions with or without photon RT for recurrent tumors. Furthermore, 15 patients with skull base tumors other than chordoma and low-grade chondrosarcoma were treated with carbon ions.

RESULTS

Actuarial 3-year local control was 81% for chordomas, 100% for chondrosarcomas, and 62% for adenoid cystic carcinomas. Local control was obtained in 15/17 patients with spinal (8/9) and sacral (7/8) chordomas or chondrosarcomas and in 11/15 patients with skull base tumors other than chordomas and low-grade chondrosarcomas, respectively. Six of 12 patients who received reirradiation are still alive without signs of tumor progression. Common Toxicity Criteria Grade 4 or Grade 5 toxicity was not observed.

CONCLUSION

Carbon ion therapy is safe with respect to toxicity and offers high local control rates for skull base tumors such as chordomas, low-grade chondrosarcomas, and unfavorable adenoid cystic carcinomas.

Die Konzeption der Heidelberger Ionentherapieanlage HICAT

The ion beam therapy facility HICAT presently under construction at the Heidelberg University Clinic will be the first clinical irradiation facility for heavy ions in Europe. Its capacity should enable the treatment of 1000 patients per year. The use of different ion species ranging from protons to oxygen under identical conditions should clarify the question of which particle species is best suited in terms of indication. A synchrotron will accelerate the particles to energies corresponding to water-equivalent ranges from 2 cm to 30 cm. An intensity-controlled raster scanning technique will be used to optimize the use of the favorable depth dose distribution of ions. The planned heavy-ion gantry will be the first world-wide. The facility should be complete in 2006.

Influence of setup errors on spinal cord dose and treatment plan quality for cervical spine tumours: a phantom study for photon IMRT and heavy charged particle radiotherapy

Tumours partly surrounding the cervical spine may be treated by conformal radiotherapy (RT) using intensity-modulated RT (IMRT) with photons or heavy charged particle RT. For both, a high setup accuracy is required to spare the radiosensitive spinal cord, if a high dose is to be delivered. A phantom study was performed to determine the variation of the dose to the spinal cord surface by predefined setup errors. The measured doses were compared to those calculated by the treatment planning programme. The influence of systematic setup errors on characteristic parameters of the treatment plan quality was quantified. The largest variation of the mean and maximum doses to the spinal cord due to setup errors was significantly larger for carbon ions than for IMRT (mean: 11.9% versus 3.9%, max: 29.2% versus 10.8% of the prescribed dose). For the comparison of measured and calculated doses, mean deviations of 3% (IMRT) and 6% (carbon ions) of the prescribed dose were obtained. These deviations have to be considered, when the spinal cord dose is assessed from the treatment plan and they may also influence the dose prescription. Carbon ions yield better values for coverage (99.9% versus 93.1%) and conformality (110% versus 126%) of the PTV as compared to IMRT, while the spinal cord is better spared. Dose distributions produced with carbon ions, however, are more sensitive to setup errors, which have to be considered during treatment.

Treatment planning intercomparison for spinal chordomas using intensity-modulated photon radiation therapy (IMRT) and carbon ions

Spinal chordomas cannot be treated with an effective dose using conventional radiation therapy (RT) without exceeding the tolerance dose of the spinal cord while ensuring sufficient target coverage at the same time. In this study we investigate the potential physical advantages of combined photon intensity-modulated radiation therapy (IMRT) and raster-scanned carbon ion RT over photon IMRT alone. For a representative patient we generated a carbon ion RT plan and a photon IMRT plan. Additionally, combined plans consisting of both carbon ions and photon IMRT were calculated using ratios of 20:40 GyE, 30:30 GyE and 40:20 GyE. The best target coverage was obtained using carbon ions alone. Using a combination of photon IMRT and carbon ions, the target coverage was better than with photon IMRT alone. Due to the applied dose constraints, the sparing of the spinal cord was comparable for all plans. Using carbon ions alone, the non-target tissue volume irradiated to at least 30 GyE/50.4 GyE was reduced by 72%/84% compared to photon IMRT alone. These advantages were evident even with combined techniques. The actually delivered dose distribution is expected to be more dependent on patient misalignment with carbon ions compared with photon IMRT. A combination of carbon ions and photon IMRT might be preferable in order to profit by the physical advantages of carbon ions while ensuring a safe treatment.

Biological dosimetry of complex ion radiation fields

We report on a set of cell survival experiments performed in complex field combinations of therapeutic 12C ion beams. CHO cells were exposed to the superposition of two or three fields of 12C ions arranged in a similar way to real patient treatments. Two-dimensional survival distributions were measured and compared with the predictions of the TRiP98 treatment planning system. Good agreement was found in general. In particular the method of tissue sparing using dose ramps could be verified.